Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555217 | 0.83 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL11570592 | 0.81 | — | — | |
| SCHEMBL3422699 | 0.79 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2 | |
| SCHEMBL24023540 | 0.79 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2 | |
| SCHEMBL11929538 | 0.77 | KMT2A (0.44) | CYP2D6HRH3KDM2B | |
| SCHEMBL15223351 | 0.77 | KMT2A (0.44) | CYP2D6HRH3KDM2B | |
| SCHEMBL24673650 | 0.76 | TSHR (0.42) | CYP2D6SMN1; SMN2 | |
| SCHEMBL24616098 | 0.76 | DRD2 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL4323995 | 0.76 | CYP2D6 (0.35) | CYP2D6SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL24616015 | 0.76 | DRD2 (0.37) | CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | CYP2D6 995/4885SMN1; SMN2 3309/4885NOS3 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.